Daxor Corporation announced the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.11 USD | +3.17% | +1.22% | -5.10% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.10% | 43.79M | |
+2.75% | 12.65B | |
+15.30% | 9.84B | |
-2.85% | 5.43B | |
+4.29% | 5.12B | |
-3.96% | 4.92B | |
+24.13% | 4.92B | |
+19.14% | 4.53B | |
+1.77% | 3.97B | |
+1.24% | 3.79B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Appoints Lisa Quartley as its First SVP, Marketing and Commercial Development